Sunshine Biopharma Warrant Stock Revenue Per Share

SBFMW Stock

USD 0.19 0.03 18.75%

Sunshine Biopharma Warrant fundamentals help investors to digest information that contributes to Sunshine Biopharma's financial success or failures. It also enables traders to predict the movement of Sunshine Stock. The fundamental analysis module provides a way to measure Sunshine Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Sunshine Biopharma stock.

		Last Reported	Projected for Next Year
	Revenue Per Share	1.8 K	1.9 K

Revenue Per Share is likely to climb to 1,872 in 2025.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Sunshine Biopharma Warrant Company Revenue Per Share Analysis

Sunshine Biopharma's Revenue per Share is a ratio of total revenue earned per one share of common stock over a single fiscal year. It is calculated by dividing sales revenue earned over 12 months by the average number of outstanding shares. Revenue used in the calculation of this ratio is typically recorded when cash or cash equivalents are exchanged for services or goods.

Current Sunshine Biopharma Revenue Per Share

1.9K

Most of Sunshine Biopharma's fundamental indicators, such as Revenue Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Sunshine Biopharma Warrant is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Sunshine Revenue Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Sunshine Biopharma is extremely important. It helps to project a fair market value of Sunshine Stock properly, considering its historical fundamentals such as Revenue Per Share. Since Sunshine Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sunshine Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sunshine Biopharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Receivables	Intangible Assets	Net Tangible Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Good Will	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments
Total Assets		1.0	-0.98	-0.94	1.0	0.98	1.0	-0.31	0.21	0.99	0.78	0.78	-0.78	0.61	0.77	-0.68	1.0	0.9	-0.58	1.0	-0.68
Total Stockholder Equity	1.0		-0.98	-0.92	1.0	0.97	1.0	-0.31	0.17	0.99	0.78	0.78	-0.75	0.58	0.75	-0.68	1.0	0.88	-0.6	1.0	-0.68
Net Debt	-0.98	-0.98		0.93	-0.98	-0.96	-0.98	0.32	-0.28	-0.95	-0.73	-0.77	0.75	-0.6	-0.77	0.53	-0.99	-0.86	0.6	-0.98	0.53
Retained Earnings	-0.94	-0.92	0.93		-0.93	-0.97	-0.94	0.24	-0.36	-0.91	-0.81	-0.81	0.91	-0.78	-0.9	0.52	-0.93	-0.93	0.49	-0.94	0.52
Accounts Payable	1.0	1.0	-0.98	-0.93		0.98	1.0	-0.31	0.2	0.99	0.78	0.77	-0.77	0.6	0.75	-0.67	1.0	0.88	-0.58	1.0	-0.67
Total Liab	0.98	0.97	-0.96	-0.97	0.98		0.98	-0.28	0.35	0.95	0.75	0.78	-0.85	0.7	0.82	-0.63	0.98	0.91	-0.49	0.98	-0.63
Total Current Assets	1.0	1.0	-0.98	-0.94	1.0	0.98		-0.31	0.22	0.98	0.77	0.78	-0.78	0.62	0.77	-0.67	1.0	0.9	-0.57	1.0	-0.67
Common Stock	-0.31	-0.31	0.32	0.24	-0.31	-0.28	-0.31		-0.06	-0.3	-0.12	-0.38	0.36	-0.31	-0.36	0.18	-0.3	-0.36	0.31	-0.31	0.18
Short Term Debt	0.21	0.17	-0.28	-0.36	0.2	0.35	0.22	-0.06		0.06	-0.14	0.3	-0.41	0.41	0.43	0.21	0.25	0.31	-0.08	0.21	0.21
Net Receivables	0.99	0.99	-0.95	-0.91	0.99	0.95	0.98	-0.3	0.06		0.83	0.76	-0.75	0.57	0.73	-0.73	0.98	0.88	-0.57	0.99	-0.73
Intangible Assets	0.78	0.78	-0.73	-0.81	0.78	0.75	0.77	-0.12	-0.14	0.83		0.63	-0.69	0.64	0.75	-0.5	0.75	0.73	-0.41	0.78	-0.5
Net Tangible Assets	0.78	0.78	-0.77	-0.81	0.77	0.78	0.78	-0.38	0.3	0.76	0.63		-0.7	0.46	0.73	-0.48	0.78	0.87	-0.72	0.79	-0.48
Property Plant Equipment	-0.78	-0.75	0.75	0.91	-0.77	-0.85	-0.78	0.36	-0.41	-0.75	-0.69	-0.7		-0.92	-0.94	0.48	-0.77	-0.9	0.26	-0.79	0.48
Current Deferred Revenue	0.61	0.58	-0.6	-0.78	0.6	0.7	0.62	-0.31	0.41	0.57	0.64	0.46	-0.92		0.92	-0.25	0.6	0.73	-0.13	0.63	-0.25
Long Term Debt	0.77	0.75	-0.77	-0.9	0.75	0.82	0.77	-0.36	0.43	0.73	0.75	0.73	-0.94	0.92		-0.33	0.76	0.9	-0.39	0.79	-0.33
Good Will	-0.68	-0.68	0.53	0.52	-0.67	-0.63	-0.67	0.18	0.21	-0.73	-0.5	-0.48	0.48	-0.25	-0.33		-0.65	-0.62	0.36	-0.68	1.0
Net Invested Capital	1.0	1.0	-0.99	-0.93	1.0	0.98	1.0	-0.3	0.25	0.98	0.75	0.78	-0.77	0.6	0.76	-0.65		0.89	-0.58	1.0	-0.65
Short Long Term Debt	0.9	0.88	-0.86	-0.93	0.88	0.91	0.9	-0.36	0.31	0.88	0.73	0.87	-0.9	0.73	0.9	-0.62	0.89		-0.54	0.91	-0.62
Capital Stock	-0.58	-0.6	0.6	0.49	-0.58	-0.49	-0.57	0.31	-0.08	-0.57	-0.41	-0.72	0.26	-0.13	-0.39	0.36	-0.58	-0.54		-0.58	0.36
Net Working Capital	1.0	1.0	-0.98	-0.94	1.0	0.98	1.0	-0.31	0.21	0.99	0.78	0.79	-0.79	0.63	0.79	-0.68	1.0	0.91	-0.58		-0.68
Short Term Investments	-0.68	-0.68	0.53	0.52	-0.67	-0.63	-0.67	0.18	0.21	-0.73	-0.5	-0.48	0.48	-0.25	-0.33	1.0	-0.65	-0.62	0.36	-0.68

Click cells to compare fundamentals

Sunshine Revenue Per Share Historical Pattern

Today, most investors in Sunshine Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sunshine Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sunshine Biopharma revenue per share as a starting point in their analysis.

Sunshine Biopharma Revenue Per Share

Timeline

Revenue per share does not take into account any of company expenses and is helpful only when comparing relative sale figures within a given industry.

Competition

Predict Sunshine Biopharma

Revenue Per Share Over Time

Sunshine Common Stock Shares Outstanding

Common Stock Shares Outstanding

26,538.02

At this time, Sunshine Biopharma's Common Stock Shares Outstanding is fairly stable compared to the past year.

Sunshine Revenue Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sunshine Biopharma's direct or indirect competition against its Revenue Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sunshine Biopharma could also be used in its relative valuation, which is a method of valuing Sunshine Biopharma by comparing valuation metrics of similar companies.

Sunshine Biopharma is currently under evaluation in revenue per share category among its peers.

Sunshine Fundamentals

	Return On Equity	-0.18
	Return On Asset	-0.11
	Profit Margin	(0.13) %
	Operating Margin	(0.13) %
	Number Of Shares Shorted	2.8 K
	Revenue	24.09 M
	Gross Profit	110.6 K
	EBITDA	(3.82 M)
	Net Income	(4.51 M)
	Cash And Equivalents	40.56 M
	Cash Per Share	1.80 X
	Total Debt	657.71 K
	Debt To Equity	8.98 %
	Current Ratio	85.09 X
	Book Value Per Share	12.52 X
	Cash Flow From Operations	(8.78 M)
	Earnings Per Share	(2.21) X
	Number Of Employees	44
	Beta	-1.04
	Total Asset	27.35 M
	Retained Earnings	(63.91 M)
	Working Capital	19.34 M
	Net Asset	27.35 M

About Sunshine Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Sunshine Biopharma Warrant's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sunshine Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sunshine Biopharma Warrant based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC